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Abstract In rheumatoid arthritis (RA) patients, weekly
intake of methotrexate (MTX) is the basic drug treatment.
This observational study aims to investigate how many
RA patients are adherent in terms of MTX intake and to
identify determinants of non-adherence. Intake of MTX
(orally or via injection) was recorded in 129 RA patients
with an electronic monitoring system (MEMS®) during
16 weeks. In addition, two adherence questionnaires, the
Medication Adherence Report Scale (MARS-5) and the
Compliance-Questionnaire-Rheumatology (CQR) as well
as a visual analogue scale (VAS) measuring MTX adher-
ence, were administered to these patients. As possible
determinants of adherence, data on demographics, disease
and treatment characteristics, depression, illness cogni-
tions, motivation, and social support were collected. Of
all participants, 58 % were fully adherent and 75 %
skipped at most one dose during 16 weeks. A better
mental health status and suffering from comorbidities
had a positive effect on adherence, while living alone
had a negative effect. These three predictors explained
30 % of the variance in MTX adherence. Of the three
self-report medication adherence measures, the VAS cor-
related the highest with the results of the electronic mon-
itoring system (r= 0.552, p= 0.01). A relatively high ad-
herence rate was observed in RA patients treated with
MTX. The determinants identified by this study could
be used to screen patients at risk for non-adherence. A
simple VAS scale seems to be an acceptable way for a
preliminary screening of MTX adherence.
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Introduction
Rheumatoid arthritis (RA) is the most prevalent inflam-
matory rheumatic disease causing joint pain, swelling, and
morning stiffness, leading to the destruction of cartilage
and bone loss, potentially resulting in important disability
[1]. Basic drug treatment consists of disease modifying
anti-rheumatic drugs (DMARDs) of which methotrexate
(MTX) is the first choice.
To achieve the disease modifying effects, medication ad-
herence is crucial. Assessing adherence and identifying rea-
sons for (non-) adherence is therefore important from a clini-
cal perspective. The way medication adherence is measured
may however be responsible for diversity in results [2].
Self-reported adherence mostly results in higher adherence
rates than electronic monitoring, which was only used in two
studies in RA patients [3, 4].
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This observational study aims to answer the following
questions:
– To what extent do RA patients take their MTX as
prescribed?
– Which factors indicate an increased risk of non-adherence
and can thus be useful for screening purposes?
– Which self-report measure, useable in daily practice, is
the most valid, compared to an electronic monitoring
system?
Materials and methods
Research field
One hundred forty-six patients who visited the ambulatory
rheumatology unit (outpatient/day clinic) of Antwerp Univer-
sity Hospital (Belgium) between September and November
2013 and who met the following inclusion criteria were invit-
ed to participate:
& Diagnosed RA according to the ACR/EULAR criteria of
2010 treatment with MTX
& Sufficient knowledge of the Dutch language
& Not suffering from severe mental disorders
Data collection
The study was approved by the ethics committee of Antwerp
university hospital (B300201318114). Patients who met the
inclusion criteria were asked by their rheumatologists or the
rheumatology nurse to participate. An informed consent was
obtained from all patients prior to the study.
Assessment of adherence
Adherence was measured using the Medication Event Moni-
toring System (MEMS®, MWV Healthcare). The intake be-
havior is quantified by the use of a medication container of
which the cap includes a chip that registers the moment of
opening [2]. A patient was considered fully adherent if over
a period of 1 week the MEMS®container was opened once or
more in accordance with the prescription. For each of the 16
consecutive weeks, every patient was given a score of 1
(opened) or 0 (not opened). The average of these 16 measure-
ments, multiplied by 100, resulted in a score of medication
adherence.
Adherence was alsomeasured bymeans of three self-report
measures. The CQR [5, 6] consists of 19 statements
concerning medication intake in which the patient indicates
to what extent (s) he agrees on a 4-point Likert scale. The
multivariate weighed model of De Klerk and colleagues pro-
poses two discriminant formulas to detect intake compliance
(≤80 and ≤50 %) [6]. The MARS-5 is an adherence measure
developed to use in patients suffering from a variety of chronic
diseases [7]. It consists of five statements with regard to as-
pects of non-adherent behaviors. Patients indicate to what ex-
tent each statement applies to them on a 5-point Likert scale
(1=always, 2=often, 3= sometimes, 4= rarely, and 5=nev-
er). By summing up the answers, a score in between 5 and 25
is obtained. A visual analogue scale ranging from Bin 0 % of
the cases^ to Bin 100 % of the cases^ was used to ask patients
to what extent they took the MTX as prescribed. Patients gave
a mark on a 10 cm line resulting in a score in between 0 and
100.
Assessment of possible determinants
We included sociodemographic characteristics, condition-
related factors, and cognitions as potential determinants of
medication adherence based on the evidence resulting
from a systematic review [8]. In addition, we added
therapy-related factors as there is also evidence for their
importance [9]. Next, determinants such as quality of life,
depression and anxiety, and patient-related characteristics
such as social support and motivation were added based
on more recent publications [10, 11].
Socio-demographic characteristics such as age, gender,
living situation, and occupational status were collected by
means of a structured questionnaire.
Condition-related factors retrieved from the medical file
were disease activity of RA assessed by means of the Disease
Activity Score 28 (DAS28) (remission status<2,6) [1], daily
functional limitations, and acquired damage to the joints,
assessed by the HAQ [12] and comorbidities. To assess so-
matic symptoms, the validated Patient Health Questionnaire
15 (PHQ-15) was used [13]. The Short Form 36 (SF36), a
validated generic instrument that measures quality of life, pro-
vided information on the patient’s physical and mental health
status [14]. Depression was assessed using the nine items of
the validated Patient Health Questionnaire 9 (PHQ-9) [15].
Anxiety was measured by means of the anxiety subscale of
the validated Dutch version of the Brief Symptom Inventory,
consisting of six items [16].
Therapy-related factors measured were disease duration,
the dosage ofMTX, themode of patient follow up, the number
of doctor visits during the last 6 months, the number of pre-
scribed pills per day, and possible side effects.
Patient-related characteristics: The IPQ-K, the Dutch
shortened version of the Illness Perception Questionnaire,
was used to measure illness cognitions [17]. Eight statements
were scored on a scale from 0 to 10. Social support was mea-
sured by means of a questionnaire concerning social support
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with the disease in general and more specific in relation to the
medication intake [18]. The motivation to take MTX was
assessed by means of the Treatment Self-Regulation Ques-
tionnaire (TSRQ), adapted to measure the medication adher-
ence. Motivation can be autonomous (internally regulated) or
coerced (externally regulated). Eleven items were rated on a
7-point Likert scale (1= totally disagree and 7= totally agree).
A subscore for autonomous and for coerced motivation was
compiled by calculating the average score of the correspond-
ing items. By subtracting the score for coerced regulation from
the score for autonomous regulation, a combined score was
calculated [19].
Statistical analysis
Differences between categorical data were analyzed using
chi-squared analysis, between continuous data with t tests. A
logistic regression analysis with as dependent variable being
fully adherent or not was carried out by a stepwise input of
independent variables that showed a significant relationship of
0.01 or lower with MTX adherence in univariate analyses,
until the best statistically significant model was found
(p<0.05). Correlations between the different measures of ad-
herence were calculated with Pearson’s correlations. The sta-
tistical analyses were performed with SPSS 21.0.
Results
Sampling
Figure 1 describes the process of inclusion.
The sample (n=129) consisted for 60 % of women. The
average age of the participants was 61 years. They had mean
disease duration of 12 years and 65 % was in remission status.
The MTX was taken orally by 64 % of the participants. Of the
total sample, 43% reported side effects of the MTX treatment.
Adherence with regard to methotrexate
Figure 2 gives a description of the number of doses of MTX
missed over a period of 16 weeks. More than half of the
participants (58 %) took faithfully each week the MTX. A
quarter skipped the medication for at least 2 weeks, corre-
sponding to less than 90 % adherence. Only 9 % failed more
than three times to take their medication and was thus less than
80 % adherent.
The MARS-5 had an acceptable internal consistency
(Cronbach’s alpha = 0.71). The mean score was 24.2
(SD=1.7). The CQR showed a poor internal consistency in
this population (Cronbach’s alpha=0.51). Following the dis-
criminant formula of De Klerk and colleagues [6] to detect
80 % taking compliance, 14.3 % of the participants were less
than 80 % adherent. The visual analogue scale indicated a
mean adherence of 94 % (SD=10.0).
Factors associated with adherence to MTX
Table 1 reports on the predictors for adherence to MTX. A
criterion of 100 % adherence was used to construct the depen-
dent variable.
The following determinants were dichotomized: living sit-
uation (living alone, yes/no) and comorbidities (yes/no). Only
independent variables that showed a significant univariate re-
lationship with the dependent variable at a 0.01 level were
entered in the logistic regression analysis: living alone, suffer-
ing from comorbidities, mental health status, and the illness
cognitions identity and perceived emotional consequences.
screening
paënt records
1140
potenally 
eligible
152
invited to 
parcipate
146
included
140
study completed
129
- diagnosis RA + treatment MTX not present 988
excluded paënts 6
- demena
- Dutch language knowledge insuﬃcient
- change of methotrexate administraon
2
3
1
lost to follow up 11
- stop MTX because of contraindicaon
- paent deceased
- MEMS lost on holiday
- MEMS accidentally in garbage bin
- did not use MEMS  or stopped prematurely
2
1
1
1
6
refusals 6
- lack of me
- bad experience with previous study parcipaon
- opposed to clinical trials
3
1
2
Fig. 1 Inclusion and retention tree
adherent:  100 % MTX intake
non adherent:  < 100 % MTX intake
n=129
Fig. 2 Medication adherence rate for methotrexate
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Suffering from comorbidities and a better mental health status
had a positive influence on medication adherence. Living
alone was negatively associated with adherence to MTX.
The association between electronic monitoring and
self-report measures of adherence proved to be different.
The scores on the visual analogue scale for adherence cor-
related moderately with the results of the electronic adherence
monitoring (r= 0.552, p< 0.001) although the VAS score
seems to overestimate adherence (see Fig. 3).
The correlation between the MARS-5 questionnaire and
the electronic monitoring system was weaker (r= 0.356,
p<0.001). As the internal consistency of the CQR was too
low, 8 questions out of 19 were deleted (items 4, 5, 8, 9, 11,
12, 16, and 19) resulting in a good consistency (Cronbach’s
alpha=0.77). There was however no significant correlation
between the results of the electronic monitoring system and
the sum score of the remaining items. In addition, no associ-
ation was found between the discriminant formula of DeKlerk
and colleagues [6] to detect 80 % taking compliance and the
results of the 80 % adherence level measured with the elec-
tronic monitoring system (X2 (2, N=104)=0.09, p=0.77).
Discussion
A large study on MTX adherence showed that only 64 % of
the participants took at least 80 % of the prescribed dose [20].
In the present study, 92 % of the patients took at least 80 % of
the prescribed dose. In a Dutch study, full adherence for meth-
otrexate was found in a small sample of patients [4]. The high
adherence rate in our study may be due to a selection bias:
possibly, patients who were less adherent did not want to
participate or did not complete the medication registration.
This concerns, however, only 17 patients out of 146. The fact
that Belgian patients only contribute for a very small part to
health care costs may also have played a role [8]. In addition,
in the Belgian context, RA patients usually see their specialist
every 6 months or even more frequently. This close follow
may also have increased the adherence rate. Another issue is
that this study collected data in only one health care center. A
larger, multicenter study might have resulted in lower adher-
ence rates. In addition, a large number of the participants had
long disease duration and most patients were in remission.
Finally, extending the MEMSmeasurement period might also
increase the validity of the results.
With respect to predictors of adherence, the negative rela-
tionship between living alone and adherence indicates that
social support has an impact on medication intake. This is
consistent with previous findings [21]. The positive influence
of comorbidity on adherence is also in accordance with other
studies [22, 23]. Finally, a better mental health status was also
associated to medication adherence in at least one other study
[11].
Adherence scores based on a visual analogue scale showed
a higher correlation with results from electronic monitoring
than the data obtained with two other self-report measures.
Table 1 Logistic regression
analysis: predictors of adherence B S.E. Wald OR 95 % CI
Socio-demographic characteristics
Living alone −1.550 0.600 6.668** 0.212 0.065–0.688
Condition related characteristics
Comorbidities 1.481 0.444 11.149** 4.398 1.844–10.493
Mental health status (SF36) 0.049 0.023 4.623* 1.050 1.004–1.098
Illness cognitions
Identity −0.113 0.096 1.386 0.893 0.739–1.078
Emotional consequences −0.140 0.086 0.025 0.987 0.833–1.168
Being adherent is defined as taking 100 % of the prescribed doses. 0 = non-adherent and 1 = adherent
*p< 0.05; **p < 0.01
n=129
r=0.552
p<0.001
y=0.33+64.01
Fig. 3 Correlation visual analogue scale and electronic adherence
monitoring
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As a consequence, a VAS scale may be used in daily practice
for a quick screening of medication adherence in patients. A
weaker correlation was found between the MARS-5 and the
electronic monitoring which is consistent with the results of an
earlier study [2]. Finally, the sum score of the CQR did not
show a significant association with the results of the electronic
monitoring. The CQR may be more appropriate to identify
determinants of treatment adherence.
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